Absolute Return Capital’s Myriad Genetics MYGN Stock Holding History

Absolute Return Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-4,964	Closed	-$186K	–	226
2015 Q3	$186K	Buy	4,964 +1,960	+65%	+$69.6K	0.01%	440
2015 Q2	$102K	Sell	3,004 -3,983	-57%	-$135K	﹤0.01%	537
2015 Q1	$247K	Buy	6,987 +1,936	+38%	+$69.3K	0.01%	530
2014 Q4	$172K	Buy	+5,051	New	+$179K	﹤0.01%	598
2014 Q3	–	Sell	-82,584	Closed	-$3.21M	–	814
2014 Q2	$3.21M	Buy	82,584 +66,159	+403%	+$2.46M	0.04%	467
2014 Q1	$562K	Buy	+16,425	New	+$509K	0.01%	813

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Absolute Return Capital's MYGN Position: Q4 2015 in Review

Absolute Return Capital sold out of Myriad Genetics (MYGN) in Q4 2015, closing a stake of 4,964 shares — an estimated $186K sold.

Absolute Return Capital first reported a position in MYGN in Q1 2014 and held it in 6 quarters. The position peaked at $3.21M in Q2 2014. 232 funds tracked by Wall St. Rank hold MYGN as of Q4 2015.

Absolute Return Capital reported no remaining Myriad Genetics position as of Q4 2015 after selling out during the quarter.
Absolute Return Capital sold 4,964 Myriad Genetics shares in Q4 2015, an estimated $186K.
Absolute Return Capital first reported a position in Myriad Genetics in Q1 2014 and held it in 6 quarters.
Absolute Return Capital's Myriad Genetics position peaked at $3.21M in Q2 2014.
232 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2015.

Based on Absolute Return Capital's 13F filing for Q4 2015.